drugset / Trial / NCT04262154
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Phase 2
Active not recruiting
28 enrolled
Memorial Sloan Kettering Cancer Center
Genentech, Inc. · collabStand Up To Cancer · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is to find out whether adding the study drug atezolizumab and stereotactic body radiotherapy (SBRT) to standard treatment with abiraterone acetate, prednisone, and Lupron® (leuprolide) is a safe and effective way to treat previously untreated metastatic prostate cancer, and to see whether the study treatment works better than the standard treatment.
Timeline
- Start
- 2020-03-03
- Primary completion
- 2025-07-07
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Background | Abiraterone acetate | Small molecule | 1000 mg | — |
| Background | Enzalutamide | Other / unclassified | 160 mg | — |
| Background | Leuprolide | Other / unclassified | — | Intramuscular |
| Background | Prednisone | Other / unclassified | 5 mg | — |